Skip to main content
Fig. 4 | Cell Communication and Signaling

Fig. 4

From: miR-146a-5p impairs melanoma resistance to kinase inhibitors by targeting COX2 and regulating NFkB-mediated inflammatory mediators

Fig. 4

Treatment resistant tumors display miR-146a/COX2 axis deregulation. a COX2 immunostaining in tumors excised from patients progressing during BRAF/MEKi therapy (Post) compared to pre-therapy matched melanoma lesions (Pre). Scale bar: 10 μm. b Lower miR-146a and higher PTGS2 and PTGES expression levels in tumors progressing in patients during BRAF/MEKi therapy (Treated, n = 12) compared to tumors from unmatched untreated patients (Untreated, n = 31). *: p < 0.05, **: p < 0.01 by Mann-Whitney U test. c Heatmap showing the gene expression pattern of PTGS2, CXCL8, PTGES, IL6, VEGFA, CD274, MCL1 in progressing tumors (Post-treatment) compared to matched pre-therapy lesions (Pre-treatment) from seven metastatic melanoma patients receiving BRAFi therapy

Back to article page

Cell Communication and Signaling

ISSN: 1478-811X